Hemanext key facts
as of Oct 2026- Developer of transfusion medical technology designed to support the transfusion medicine community in efforts to save lives and improve patient outcomes.
- Hemanext is valued at approximately $115.0M as of Oct 2026 (last reported valuation).
- It has raised $220.3M across 6 recorded rounds; the latest was Early Stage VC ($20.0M) in Jul 2025.
- Notable investors include Eduardo Avayu Family Office, Grabe Family Office, Omega Advisors, Testa Family Office, Antaeus Enterprises — 12 tracked in total.
- Hemanext has filed 7 Form Ds with the SEC since 2020, most recently Aug 2025 ($20.0M sold to 29 investors).
- Status: Privately Held (backing).
Hemanext's last reported valuation, Oct 2024. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch Hemanext: the Monday email on marks, rounds and moves
Hemanext funding rounds
6 roundsWho backs Hemanext
12+Hemanext valuation
Hemanext's last reported valuation was $115 million in Oct 2024. No priced round, secondary trade or fund mark has surfaced since.
How much has Hemanext raised?
Hemanext has raised $220 million across 6 recorded rounds since 2019. The largest was a $5 million early-stage round in Dec 2023; the most recent was a $20 million early-stage round in Jul 2025.
Hemanext has filed 7 Form Ds with the SEC since 2020, most recently in Aug 2025 ($20 million sold to 29 investors).
Hemanext investors
12 investors are on record for Hemanext, including Eduardo Avayu Family Office, Grabe Family Office, Omega Advisors and Testa Family Office. The early-stage round in Jul 2025 drew 29 investors.
About Hemanext
Developer of transfusion medical technology designed to support the transfusion medicine community in efforts to save lives and improve patient outcomes. The company offers novel storage methods to potentially extend the shelf life of refrigerated red blood cells while enhancing the quality across the storage cycle, enabling healthcare providers to promote improvements in the quality, safety, and efficacy, and reduce the cost of transfusion therapy.
- Sector
- Healthcare
- HQ
- Lexington, MA, United States
- Founded
- 2000
- Employees
- 52
- Website
- hemanext.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.